Since 1952, the National Association of Letter Carriers, the nationwide union of US postal delivery workers, has supported MDA as its charity of choice — and raised more than $100 million through local fundraisers that have showcased workers’ creativity and dedication to MDA’s mission of transforming the lives of people living with neuromuscular disease through . . .
Genetic testing has a critical role in patients’ care as genetic information helps physicians to distinguish between types of neuromuscular disorders, informs prognosis and treatment decisions, and determines patients’ eligibility for new and emerging therapies. Selecting the right genetic test and incorporating genetic information to reach a diagnosis and formulate a treatment plan require deep . . .
Today, Solid Biosciences released a letter to the Duchenne muscular dystrophy (DMD) community regarding the decision by the US Food and Drug Administration (FDA) to place the company’s IGNITE DMD clinical trial on hold because the latest child dosed experienced a serious adverse event (SAE). The full letter follows. Letter to the Duchenne Community: Update . . .
#GivingTuesday, annually held immediately after the Black Friday and Cyber Monday holiday shopping days following Thanksgiving, falls late this year on Dec. 3. But here at MDA, we’re already planning on how we can all join together during this Season of Will to celebrate the loved ones we know impacted by muscular dystrophy, ALS, and . . .
Today, Roche Genentech released a letter to the Duchenne muscular dystrophy (DMD) community regarding its decision to discontinue its DMD clinical development program. The full letter follows. Letter to the DMD community from Roche Genentech: Dear members of the Duchenne community, We are writing to share with you unfortunate news about our clinical development program . . .
MDA’s new Medical Education department was established in response to the growing need for clinician education in neuromuscular diseases. We are pleased to present our first CME-accredited webinar highlighting the treatment landscape for spinal muscular atrophy (SMA). SMA is a neuromuscular disorder that often presents as hypotonia and weakness shortly after birth. SMA is characterized . . .
On Oct. 30, AveXis released a letter to the spinal muscular atrophy (SMA) community regarding a decision by the US Food and Drug Administration (FDA) to place a partial hold on clinical trials for intrathecal (IT) administration of AVXS-101. The full letter follows. The order stops enrollment of patients in the high-dose group of AveXis’ . . .
Throughout the fall and winter months, MDA Engage Social Gatherings will be taking place throughout the country. These gatherings facilitate community through establishing opportunities for families, clinicians, researchers, volunteers, sponsors, supporters, and MDA staff to connect in a casual social setting. Participants tell their stories and are united within the neuromuscular community, supporting each other . . .
Researchers at Amicus Therapeutics are looking for adolescents (age 12-18) with late-onset Pompe disease (LOPD) to participate in a phase 3 study. The goal of the study is to evaluate the safety and efficacy of ATB200/AT2221, which researchers hope may improve muscle function and respiratory function compared to the standard of care. Participants will be . . .
This September, at Casey’s General Stores in 16 states across the Midwest, employees have been doing more than serving guests. They’ve been serving the MDA community, too, inviting store guests to round purchase totals up to the nearest whole dollar to support individuals and families impacted by neuromuscular disease. Now in its 13th year of . . .